argenx to report half year 2019 financial results and second quarter business update on August 1, 2019
July 25 2019 - 1:00AM
July 25, 2019 Breda,
the Netherlands / Ghent, Belgium – argenx (Euronext &
Nasdaq: ARGX), a clinical-stage biotechnology company developing a
deep pipeline of differentiated antibody-based therapies for the
treatment of severe autoimmune diseases and cancer, today announced
that it will host a conference call and live audio webcast on
Thursday, August 1, 2019 at 3:00 pm CEST (9:00 am ET) to discuss
its financial results for the first half of 2019 and to provide a
second quarter business update and outlook for the remainder of the
year.
To participate in the conference call and
Q&A session, please select your phone number below and use the
confirmation code 7539308. The live webcast may be
accessed on the homepage of the argenx website at www.argenx.com or
by clicking here.
Shortly after the webcast, a replay will be made
available on the argenx website.
Dial-in numbers:Please dial in
5–10 minutes prior to 3 pm CEST/ 9 am ET using the number and
confirmation code below.
Confirmation Code: 7539308
Belgium
+32 (0)2 400 9874 Belgium
0800 48740France
+33 (0)1 767
00794France
0805 103028 Netherlands
+31 (0)20 714
3545Netherlands
0800 0249557United Kingdom
+44 (0)844 571 8892United Kingdom
0800 376 7922United
States
+1 (631) 510 7495United
States
+1 (866) 966 1396
About argenxargenx is a
clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe
auto-immune diseases and cancer. The company is focused on
developing product candidates with the potential to be either
first-in-class against novel targets or best-in-class against
known, but complex, targets in order to treat diseases with a
significant unmet medical need. argenx’s ability to execute on this
focus is enabled by its suite of differentiated technologies. The
SIMPLE Antibody™ Platform, based on the powerful llama immune
system, allows argenx to exploit novel and complex targets, and its
three complementary Fc engineering technologies are designed to
expand the therapeutic index of its product candidates.
www.argenx.com
For further information, please contact:
Beth DelGiacco, Vice President Investor Relations+1 518 424
4980bdelgiacco@argenx.com
Marieke Vermeersch, Corporate Communications & Investor
Relations Consultant+32 (0)479 490 603+32 (0)3 290 00
50mvermeersch@argenx.com
Forward-looking Statements
The contents of this announcement include
statements that are, or may be deemed to be, “forward-looking
statements.” These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“believes,” “estimates,” “anticipates,” “expects,” “intends,”
“may,” “will,” or “should” and include statements argenx makes
concerning the intended results of its strategy. By their
nature, forward-looking statements involve risks and uncertainties
and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. argenx’s actual results
may differ materially from those predicted by the forward-looking
statements as a result of various important factors, including
argenx’s expectations regarding its the inherent uncertainties
associated with competitive developments, preclinical and clinical
trial and product development activities and regulatory approval
requirements; argenx’s reliance on collaborations with third
parties; estimating the commercial potential of argenx’s product
candidates; argenx’s ability to obtain and maintain protection of
intellectual property for its technologies and drugs; argenx’s
limited operating history; and argenx’s ability to obtain
additional funding for operations and to complete the development
and commercialization of its product candidates. A further list and
description of these risks, uncertainties and other risks can be
found in argenx’s U.S. Securities and Exchange Commission (SEC)
filings and reports, including in argenx’s most recent annual
report on Form 20-F filed with the SEC as well as subsequent
filings and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. argenx undertakes no obligation to publicly update or
revise the information in this press release, including any
forward-looking statements, except as may be required by law.
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Apr 2023 to Apr 2024